Summary
106 previously untreated breast cancer patients have been immunohistochemically analysed for EGF-R, ER, Ki67, and c-erbB-2 product. All patients received assessable endocrine therapy following disease progression. Significant associations were observed between EGF-R and ER (inverse) and Ki67 (direct). No association was observed between EGF-R and the c-erbB-2 product. EGF-R expression was significantly associated with the loss of endocrine sensitivity in breast cancer. This was observed in both ER positive and negative disease. In ER positive breast cancers, EGF-R expression had no significant influence on the quality of tumour remissions. Further sub-classification of the ER/EGF-R data by Ki67 immunostaining showed that in ER+/EGF-R- disease, increasing proportions of Ki67 positive cells were associated with a decline in the numbers of women experiencing good quality tumour remissions. A similar trend was also observed in ER+/EGF-R+ tumours. The presence of c-erbB-2 protein product did not influence endocrine sensitivity in any of the ER/EGF-R sub-groups.
References
Jensen EV, Block GE, Smith S: Hormone dependency of breast cancer. Recent Results Cancer Res 42: 55–76, 1973
McGuire WL, Carbone PP, Vollmer EP: Estrogen Receptors in Human Breast Cancer. Raven Press, New York, 1975
Campbell FC, Blamey RW, Elston CW, Morris AH, Nicholson RI, Griffiths K, Haybittle JL: Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet ii:1317–1319, 1981
Sutton R, Campbell M, Cooke T, Nicholson RI, Griffiths K, Taylor I: Predictive power of progesterone receptor status in early breast carcinoma. Br J Surg 74:223–226, 1987
Manning DL, Nicholson RI, Eaton CL: Role of estrogens and growth factors in the aetiology of breast cancer. Recent Adv Endocrinol Metab 4:133–149, 1992
Nicholson RI, Eaton CL, Manning DL: New developments in the endocrine management of breast cancer. Recent Adv Endocrinol Metab 4:151–166, 1992
King RJB: Progression from steroid sensitive to insensitive state in breast tumours. Cancer Surveys 14:131–146, 1992
Manning DL, Nicholson RI: Detection and clinical significance of oncogenes in breast cancer.In: Walker MR, Rapley R (eds) Molecular and Antibody Probes in Diagnosis. John Wiley & Sons, Chichester, 1993, pp 75–95
Klijn JGM, Berns PMJJ, Schmitz PIM, Foekens JA: The clinical significance of epidermal growth factor receptor in human breast cancer: A review on 5232 patients. Endocrine Reviews 13:3–17, 1992
Nicholson RI, McClelland RA, Finlay P, Eaton CL, Gullick WL, Dixon AR, Robertson JFR, Ellis IO, Blamey RW: Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 29A:1018–1023, 1993
Nicholson S, Halcrow P, Farndon JR, Sainsbury JRC, Chambers P, Harris AL: Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet i:182–185, 1989
Nicholson S, Wright C, Sainsbury JRC, Farndon JR, Harris AL: Epidermal growth factor receptor as a marker of poor prognosis in node negative patients: Neu and tamoxifen failure. J Steroid Biochem Mol Biol 37:811–814, 1990
McClelland RA, Finlay P, Dixon AR, Robertson JFR, Ellis IO, Blamey RW, Nicholson RI: Epidermal growth factor receptor and estrogen receptor expression in breast cancer: Relationship to endocrine sensitivity. Life Sciences - Oncol, in press
Nicholson RI, Bouzubar N, Walker KJ, McClelland RA, Dixon AR, Robertson JFR, Ellis IO, Blamey RW: Hormone sensitivity in breast cancer: influence of heterogeneity of estrogen receptor expression and cell proliferation. Eur J Cancer 27:908–913, 1991
Nicholson RI, McClelland RA, Gee JMW, Manning DL, Cannon P, Robertson JFR, Ellis IO, Blamey RW: Transforming growth factor α and endocrine sensitivity in breast cancer. Submitted
Elston CW, Blamey RW, Johnson J, Bishop HM, Haybittle JL, Griffiths K: The relationship of oestradiol receptor and histological tumour differentiation with prognosis in human primary carcinoma.In: Mouridsen HT, Palshof T (eds) Breast Cancer, Experimental and Clinical Aspects. Pergamon Press, 1980, pp 59–62
Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Rubens R: Assessment of response to therapy in advanced breast cancer. Cancer 39:1289–1293, 1977
British Breast Group. Assessment of response to treatment in advanced breast cancer. Lancet ii:38–39, 1974
Walker KJ, Bouzubar N, Robertson JFR, Ellis IO, Elston CW, Blamey RW, Wilson DW, Griffiths K, Nicholson RI: Immunocytochemical localisation of estrogen receptor in human breast cancer. Cancer Res 48:6517–6522, 1988
Bouzubar N, Walker KJ, Griffiths K, Ellis IO, Elston CW, Robertson JFR, Blamey RW, Nicholson RI: Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer 59:943–947, 1989
Lewis S, Locker A, Todd JH, Bell JA, Nicholson RI, Elston CW, Blamey RW, Ellis IO: Expression of epidermal growth factor receptor in breast carcinoma. J Clin Pathol 43:385–389, 1990
Sharma AK, Horgan K, McClelland RA, Douglas-Jones AG, Van Agthoven T, Dorssers LCJ, Nicholson RI: Dual immunohistochemical assay for oestrogen and epidermal growth factor receptors in tumour cell lines. Br J Cancer, submitted
Long B, McKibben BM, Lynch M, van den Berg HW: Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer cell line. Br J Cancer 65:865–869, 1992
Walker KJ, McClelland RA, Candlish W, Blamey RW, Nicholson RI: Heterogeneity of oestrogen receptor expression in normal and malignant breast tissue. Eur J Cancer 28:34–37, 1992
Walker KJ, Price-Thomas JM, Candlish W, Nicholson RI: Influence of the antioestrogen tamoxifen on normal breast tissue. Br J Cancer 64:764–768, 1991
Nicholson RI: Why ER level may not reflect endocrine responsiveness in breast cancer. Rev Endocr Related Cancer 40:25–28, 1992
Hennet T, Bertoni G, Richter C, Peterhans E: Expression of the BCL-2 protein enhances survival of mouse fibrosarcoid cells in tumour necrosis factor-mediated cytotoxicity. Cancer Res 53:1456–1460, 1993
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nicholson, R.I., McClelland, R.A., Gee, J.M.W. et al. Epidermal growth factor receptor expression in breast cancer: Association with response to endocrine therapy. Breast Cancer Res Tr 29, 117–125 (1994). https://doi.org/10.1007/BF00666187
Issue Date:
DOI: https://doi.org/10.1007/BF00666187